Wyeth Q3
This article was originally published in The Tan Sheet
Executive Summary
Advil revenues increased 18% to $178 mil. in the fiscal third quarter, Wyeth announces during an Oct. 18 analysts call. The brand drove Consumer Healthcare sales worldwide up 8% to $715 mil. in Q3; the division was boosted slightly by sales of Centrum, which advanced 1% to $174 mil. during the period, according to Wyeth. "Adding to our brands was a stronger consumer heritage in this business, our new opportunities such as Advil PM and our recently launched Centrum Cardio," the firm says. The company's worldwide net sales grew 9% to $5.6 bil., though net profit fell slightly to $1.15 bil. versus $1.16 bil. in the prior-year quarter, due in part to charges related to productivity initiatives. President and CEO-elect Bernard Poussot made his first presentation during the call since the firm announced he would replace Robert Essner as CEO in January (1"The Tan Sheet" Oct. 1, 2007, In Brief)...